News
Viatris Stock: Bull vs. Bear
Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: SARTORIUS AG: Sartorius maintains high profitability despite the expected temporary declines in the first half of 2023
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Better Pharma Buy: Viatris vs. Pfizer
Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their
Why Amarin Stock Is Sinking Today
Shares of Amarin (NASDAQ: AMRN) were sinking 22.7% as of 10:56 a.m. ET on Wednesday. The steep decline came after the drugmaker announced an organizational restructuring after the market close on
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Shares of Masimo Are Dropping Tuesday
Shares of Masimo (NASDAQ: MASI) were down by 18.5% as of 1:30 p.m. on Tuesday. The patient monitoring company announced preliminary numbers for the second quarter after the markets closed on Monday
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
EQS-News: SARTORIUS AG: Sartorius completes acquisition of Polyplus
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Better High-Yield Dividend Stock: Altria or Viatris?
If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Shares of Silk Road Medical Are Dropping Wednesday
Shares of Silk Road Medical (NASDAQ: SILK) were down more than 33% as of 12:30 p.m. on Wednesday after the Centers for Medicare & Medicaid Services (CMS) announced a proposed change that could
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Here's Why Novocure Stock Dropped 42% in June
Novocure (NASDAQ: NVCR) shares dropped after publishing the results of an important clinical trial. The headlines looked positive at first glance, but the study raised concerns that lung cancer
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?
For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining